At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,105 enrolled
Drug / intervention
Nerinetide (NA-1), 2.6 mg/kg +1 moredrug
Likely dose
Nerinetide (NA-1), 2.6 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy
In Brief
A Phase 3 clinical trial evaluating Nerinetide (NA-1), 2.6 mg/kg and Placebo for Stroke, Acute. Completed, enrolled 1,105 participants across 50 sites in 8 countries.
Detailed Summary
The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, Nerinetide (NA-1), in reducing global disability in subjects with major acute ischemic stroke (AIS) with a small established infarct core and with good collateral circulation who are selected for endovascular revascularization.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke, Acute
CountriesAustralia, Canada, Germany, Ireland, South Korea, Sweden, United Kingdom, United States
CollaboratorsUniversity of Calgary
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartMar 2017
Primary CompletionNov 2019
TodayJul 2026
First PostedOct 11, 2016
Enrollment StartMar 1, 2017
Primary CompletionNov 20, 2019
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 9.7 years ago
Interventions
Nerinetide (NA-1), 2.6 mg/kgdrug
Single intravenous infusion of nerinetide over 10 ± 1 minutes
Placebodrug
Placebo Comparator: Placebo